Page 451 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 22 Soft Tissue Sarcomas 429

140. Demetriou JL, Brearley MJ, Constantino-Casas F, et al.: Inten- 162. Al-Dissi AN, Haines DM, Singh B, et al.: Immunohistochemical
tional marginal excision of canine limb soft tissue sarcomas fol- expression of vascular endothelial growth factor and vascular endo-
lowed by radiotherapy, J Small Anim Pract 53:174–181, 2012. thelial growth factor receptor in canine cutaneous fibrosarcoma, J
VetBooks.ir 141. Kung MBJ, Poirier VJ, Dennis MM, et al.: Hypofractionated radia- 163. Avallone G, Stefanello D, Boracchi P, et al.: Growth factors and
Com Pathol 141:229–236, 2009.
tion therapy for the treatment of microscopic canine soft tissue sar-
coma, Vet Comp Oncol 14:135–145, 2016.
52:1034–1040, 2015.
142. McChesney SL, Withrow SJ, Gillette EL, et al.: Radiotherapy of COX2 expression in canine perivascular wall tumors, Vet Pathol
soft tissue sarcomas in dogs, J Am Vet Med Assoc 194:60–63, 1989. 164. de Queiroz GF, Dagli MLZ, Meira SA, et al.: Serum vascular endo-
143. Hilmas DE, Gillett EL: Radiotherapy of spontaneous fibrous con- thelial growth factor in dogs with soft tissue sarcomas, Vet Comp
nective-tissue sarcomas in animals, J Natl Cancer Inst 56:365–368, Oncol 11:230–235, 2013.
1976. 165. Dernell WS, Withrow SJ, Straw RC, et al.: Intracavitary treatment
144. Banks WC, Morris E: Results of radiation treatment of naturally of soft tissue sarcomas in dogs using cisplatin in a biodegradable
occurring animal tumors, J Am Vet Med Assoc 166:1063–1064, polymer, Anticancer Res 17:4499–4505, 1997.
1975. 166. Havlicek M, Straw RC, Langova V, et al.: Intra-operative cisplatin
145. Richardson RC, Anderson VL, Voorhees WD, et al.: Irradiation- for the treatment of canine extremity soft tissue sarcomas, Vet Comp
hyperthermia in canine hemangiopericytomas: large-animal model Oncol 7:122–129, 2009.
for therapeutic response, J Natl Cancer Inst 73:1187–1194, 1984. 167. Bergman NS, Urie BK, Pardo AD, et al.: Evaluation of local toxic
146. Lawrence J, Forrest L, Adams W, et al.: Four-fraction radiation effects and outcomes for dogs undergoing marginal tumor excision
therapy for macroscopic soft tissue sarcomas in 16 dogs, J Am Anim with intralesional cisplatin-impregnated bead placement for treat-
Hosp Assoc 44:100–108, 2008. ment of soft tissue sarcomas: 62 cases (2009-2012), J Am Vet Med
147. Plavec T, Kessler M, Kandel B, et al.: Palliative radiotherapy as Assoc 248:1148–1156, 2016.
treatment for non-resectable soft tissue sarcomas in the dog – a 168. Marconato L, Comastri S, Lorenzo MR, et al.: Postsurgical intra-
report of 15 cases, Vet Comp Oncol 4:98–103, 2006. incisional 5-fluorouracil in dogs with incompletely resected,
148. Cancedda S, Marconato L, Meier V, et al.: Hypofractionated radio- extremity malignant spindle cell tumours: a pilot study, Vet Comp
therapy for macroscopic canine soft tissue sarcoma: a retrospective Oncol 5:239–249, 2007.
study of 50 cases treated with a 5 x 6 Gy protocol with or without 169. Bostock DE, Dye MT: Prognosis after surgical excision of canine
metronomic chemotherapy, Vet Radiol Ultrasound 57:75–83, 2016. fibrous connective tissue sarcomas, Vet Pathol 17:581–588, 1980.
149. Tollett MA, Duda L, Brown DC, et al.: Palliative radiation therapy 170. Evans SM: Canine hemangiopericytoma: a retrospective analysis of
for solid tumors in dogs: 103 cases (2007-2011), J Am Vet Med response to surgery and orthovoltage radiation, Vet Radiol 28:13–
Assoc 248:72–82, 2016. 16, 1987.
150. McDonald C, Looper J, Greene S: Response rate and duration 171. Hauck M: Feline injection site sarcomas, Vet Clin North Am Small
associated with a 4 Gy 5 fraction palliative radiation protocol, Vet Anim Pract 33:553–557, 2003.
Radiol Ultrasound 53:358–364, 2012. 172. Hendrick MJ, Goldschmidt MH, Shofer FS, et al.: Postvaccinal
151. Kalnicki S, Bloomer W: Radiation therapy in the treatment of bone sarcomas in the cat: epidemiology and electron probe microanalyti-
and soft tissue sarcomas, Philadelphia, 1992, Saunders. cal identification of aluminum, Cancer Res 52:5391–5394, 1992.
152. MacLeod DA, Thrall DE: The combination of surgery and radia- 173. Hendrick MJ, Goldschmidt MH: Do injection site reactions
tion in the treatment of cancer. A review, Vet Surg 18:1–6, 1989. induce fibrosarcomas in cats? J Am Vet Med Assoc 199:968, 1991.
153. Cheng EY, Dusenbery KE, Winters MR, et al.: Soft tissue sarco- 174. Hendrick MJ, Shofer FS, Goldschmidt MH, et al.: Comparison
mas: preoperative versus postoperative radiotherapy, J Surg Oncol of fibrosarcomas that developed at vaccination sites and at nonvac-
61:90–99, 1996. cination sites in cats: 239 cases (1991-1992), J Am Vet Med Assoc
154. O’Sullivan B, Davis AM, Turcotte R, et al.: Preoperative versus 205:1425–1429, 1994.
postoperative radiotherapy in soft-tissue sarcoma of the limbs: a 175. Kass PH, Barnes WG, Spangler WL, et al.: Epidemiologic evidence
randomised trial, Lancet 359:2235–2241, 2002. for a causal relation between vaccination and fibrosarcoma tumori-
155. Al-Absi E, Farrokhyar F, Sharma R, et al.: A systematic review and genesis in cats, J Am Vet Med Assoc 203:396–405, 1993.
meta-analysis of oncologic outcomes of pre- versus postoperative 176. Macy DW, Hendrick MJ: The potential role of inflammation in
radiation in localized resectable soft-tissue sarcoma, Ann Surg Oncol the development of postvaccinal sarcomas in cats, Vet Clin North
17:1367–1374, 2010. Am Small Anim Pract 26:103–109, 1996.
156. Selting KA, Powers BE, Thompson LJ, et al.: Outcome of dogs with 177. Hendrick MJ, Kass PH, McGill LD, et al.: Postvaccinal sarcomas in
high-grade soft tissue sarcomas treated with and without adjuvant cats, J Natl Cancer Inst 86:341–343, 1994.
doxorubicin chemotherapy: 39 cases (1996-2004), J Am Vet Med 178. Kass PH, Spangler WL, Hendrick MJ, et al.: Multicenter case-con-
Assoc 227:1442–1448, 2005. trol study of risk factors associated with development of injection-
157. Payne SE, Rassnick KM, Northrup NC, et al.: Treatment of vascu- site sarcomas in cats, J Am Vet Med Assoc 223:1283–1292, 2003.
lar and soft-tissue sarcomas in dogs using an alternating protocol of 179. Dean R, Adams V, Whitbread T, et al.: Study of feline injection site
ifosfamide and doxorubicin, Vet Comp Oncol 1:171–179, 2003. sarcomas, Vet Rec 159:641–642, 2006.
158. Sarcoma Meta-Analysis Collaboration: Adjuvant chemotherapy for 180. Day MJ, Schoon HA, Magnol JP, et al.: A kinetic study of his-
localised resectable soft-tissue sarcoma of adults: meta-analysis of topathological changes in the subcutis of cats injected with non-
individual data, Lancet 350:1647–1654, 1997. adjuvanted and adjuvanted multi-component vaccines, Vaccine
159. Komdeur R, Hoekstra HJ, van den Berg E, et al.: Metastasis in 25:4073–4084, 2007.
soft tissue sarcomas: prognostic criteria and treatment perspectives, 181. Shaw SC, Kent MS, Gordon IK, et al.: Temporal changes in char-
Cancer Metastasis Rev 21:167–183, 2002. acteristics of injection-site sarcomas in cats: 392 cases (1990-2006),
160. Burton JH, Mitchell L, Thamm DH, et al.: Low-dose cyclo- J Am Vet Med Assoc 234:376–380, 2009.
phosphamide selectively decreases regulatory T cells and inhibits 182. Coyne MJ, Reeves NCP, Rosen DK, et al.: Estimated prevalence
angiogenesis in dogs with soft tissue sarcomas, J Vet Intern Med of injection sarcomas in cats during 1992, J Am Vet Med Assoc
25:920–926, 2011. 210:249–251, 1997.
161. de Queiroz GF, Dagli ML, Fukumasu H, et al.: Vascular endothe- 183. Gober GM, Kass PH: World Wide Web-based survey of vaccina-
lial growth factor expression and microvascular density in soft tissue tion practices, postvaccinal reactions, and vaccine site-associated
sarcomas in dogs, J Vet Diagn Invest 22:105–108, 2010. sarcomas in cats, J Am Vet Med Assoc 2002 220:1477–1482, 2002.